European Pharmaceutical Review

JULY 20, 2023

Dr Baghirzade continued, highlighting that since a particular defining moment for the industry in the late 90s, which resulted in an unfortunate patient fatality, “there is a lot more focus on safety” in gene therapy clinical trials today. For cell and gene therapy, a “big issue” she stated, was the complexity of manufacturing.

Consulting 74

Consulting Manufacturing Side effects Safety 74

European Pharmaceutical Review

DECEMBER 12, 2023

As a biotech, what work does Innate Pharma do in the biopharma industry? A favorable safety profile was also observed. Beyond Sezary Syndrome, lacutamab showed also preliminary safety and efficacy in TELLOMAK on the first 21 patients having KIR3DL2-expressing Mycosis fungoides with an encouraging global response rate of 28.6

Pharma 124

Pharma Engineering Safety Patients 124

Pharmaceutical Technology

AUGUST 26, 2008

“The inherent advantages of biopharma are that it allows you to pursue therapies against targets that are not small molecule therapies, for example by targeting protein-protein interactions and targeting GPCRs (G-protein coupled receptors),” he says. “Biotechnology has exploded across the industry. .”

Pharmaceutical 40

Pharmaceutical Manufacturing Biopharma Medicine 40